Max W. Sung
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
Papers in
- Hepatology 43
- Hepatocellular Carcinoma Treatment and Prognosis 44
- Oncology 41
- Cancer Immunotherapy and Biomarkers 14
- Pancreatic and Hepatic Oncology Research 12
- Lung Cancer Research Studies 8
- Colorectal Cancer Treatments and Studies 8
- Co-authors
- Myron Schwartz (27 shared papers)Jonathan D. Schwartz (5 shared papers)Charles M. Miller (4 shared papers)Sukru Emre (3 shared papers)Sasan Roayaie (2 shared papers)Shu‐Hsia Chen (6 shared papers)Johnny Kao (6 shared papers)John Mandeli (7 shared papers)
- Journals
- Journal of Clinical Oncology (22 papers)Annals of Oncology (5 papers)Cancer (4 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)PLoS ONE (2 papers)
- Partner nations
- United StatesJapanUnited Kingdom
In The Last Decade
Max W. Sung
81 papers receiving 4.0k citations
Max W. Sung's Hit Papers
Peers
Comparison fields: 5 of 91
- Hepatology 2.0k
- Oncology 1.2k
- Immunology 608
- Cancer Research 368
- Pathology and Forensic Medicine 393
Countries citing papers authored by Max W. Sung
This map shows the geographic impact of Max W. Sung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max W. Sung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max W. Sung more than expected).
Fields of papers citing papers by Max W. Sung
This network shows the impact of papers produced by Max W. Sung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max W. Sung. The network helps show where Max W. Sung may publish in the future.
Co-authors
The 25 scholars most cited alongside Max W. Sung, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 86 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 873 |
| 2 | 2009 | 432 | |
| 3 | 2004 | 356 | |
| 4 | 2002 | 307 | |
| 5 | 2002 | 201 | |
| 6 | Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. | 2003 | 176 |
| 7 | 1996 | 110 | |
| 8 | 2020 | 104 | |
| 9 | 2018 | 104 | |
| 10 | 2021 | 101 | |
| 11 | 2015 | 91 | |
| 12 | 2020 | 84 | |
| 13 | 2018 | 81 | |
| 14 | 2001 | 76 | |
| 15 | 2009 | 75 | |
| 16 | 2013 | 69 | |
| 17 | A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. | 1995 | 65 |
| 18 | 2012 | 64 | |
| 19 | 2012 | 56 | |
| 20 | 2020 | 55 |
About Max W. Sung
Max W. Sung is a scholar working on Hepatology, Oncology, Epidemiology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 86 papers that have together received 4.1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (44 papers), Cancer Immunotherapy and Biomarkers (14 papers), Pancreatic and Hepatic Oncology Research (12 papers), Lung Cancer Research Studies (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Neuroendocrine Tumor Research Advances (6 papers). The work is most often cited by research in Hepatology (2.0k citations), Oncology (1.2k citations), Immunology (608 citations), Cancer Research (368 citations) and Pathology and Forensic Medicine (393 citations). Max W. Sung has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Myron Schwartz, Jonathan D. Schwartz, Charles M. Miller, Sukru Emre, Sasan Roayaie, Shu‐Hsia Chen, Johnny Kao, John Mandeli, Masatoshi Kudo and Ari David Baron. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.